Lv3
376 积分 2025-02-06 加入
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study
20天前
已完结
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1
21天前
已完结
CD40 agonist mitazalimab with mFOLFIRINOX in untreated metastatic pancreatic cancer: Biomarkers associated with outcomes from OPTIMIZE-1
21天前
已完结
Therapeutic targeting of tumour myeloid cells
23天前
已完结
Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment
23天前
已完结
Genetic engineering of systemically injectable oncolytic viruses for pyroptosis-accelerated cancer virotherapy
25天前
已完结
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
25天前
已完结
Oncolytic virus and immunogenic cell death in cancer therapy
25天前
已完结
Inference of upstream-mutation and metabolomic-signature causality identifies prognostic biomarkers and therapeutic targets in pancreatic cancer
25天前
已完结
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
25天前
已完结
皖公网安备34019202002308
